Crossmark

ASO Visual Abstract: Interpreting the BREAST-Q for Breast-Conserving Therapy—Minimal Important Differences and Clinical Reference Values

Published Online: 2023-04-26

Published Print: 2023-07

Authors

Chu, Jacqueline J.

Tadros, Audree B.

Gallo, Lucas

Mehrara, Babak J.

Morrow, Monica

Pusic, Andrea L.

Voineskos, Sophocles H.

Nelson, Jonas A.
License Information

Text and Data Mining valid from 2023-04-26

Version of Record valid from 2023-04-26
More Information

Article History

First Online: 26 April 2023

Disclosures

: The preparation of this study was supported in part by NIH/NCI Cancer Center Support Grant P30 CA008748 to Memorial Sloan Kettering Cancer Center, and this study was presented in poster format at the 44th Annual San Antonio Breast Cancer Symposium, 7–10 December 2021, San Antonio, TX. Dr. Babak Mehrara reports receipt of an investigator-initiated grant from Pfizer, Regeneron, and Puretech, receipt of royalty payments from Puretech, and an advisory position with Mediflix. Dr. Andrea L. Pusic is a codeveloper of the BREAST-Q and receives totalities when it is used in for-profit, industry-sponsored clinical trials. All other authors have no conflict of interest to disclose.

Document is current